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Rheumatoid arthritis biomarkers
With the success of biologicals in the treatment of rheu-
matoid arthritis (RA), such as inﬂ iximab, adalimumab 
(anti-TNF), rituximab (anti-B-cell), and tocilizumab 
(anti-IL-6), the armamentarium of physicians is expand-
ing so that personalized medicine is within our reach. 
Th e study of Satoko Takei and colleagues [1] in this issue 
of Arthritis Research & Th erapy describes a new serum 
biomarker with clear potential of becoming a valuable 
tool for the pharmaco diagnosis of RA. Biomarker tests 
that are currently available are failing to guide therapeutic 
decision making. C-reactive protein (CRP) and serum 
amyloid protein are sensitive markers of disease activity 
but blood levels often do not correlate with the obtained 
therapeutic eﬀ ect. Th e same holds true for IgM 
rheumatoid factor and especially for anti-cyclic 
citrullinated protein antibodies, although the latter are 
speciﬁ c for RA and of great prognostic value for the 
outcome of disease [2]. It is important to monitor disease 
activity during therapy in order to adjust, change or even 
stop therapy when necessary. Th is is the reason that the 
search for new biomarkers that can be used to monitor or 
even predict therapeutic eﬀ ectiveness is still ongoing.
Biomarkers identifi ed by -omics
Th e major problem is that RA is a heterogeneous disease, 
with disease course and extent of connective tissue 
destruction varying considerably among patients. Histo-
logical evaluation of the inﬂ amed synovium conﬁ rms the 
heterogeneity in RA, and cDNA microarray analysis of 
synovial tissue showed that, for example, STAT1 (signal 
tranducing and activator of transcription-1) gene 
expression distinguishes between RA subtypes [3]. For 
the diagnosis and management of disease, however, the 
genetic analysis of the inﬂ amed synovial tissue is 
cumbersome. Blood is a highly dynamic environment, 
communicating with practically every tissue in the body, 
and is thus proposed as a ‘sentinel tissue’ that reﬂ ects 
disease progression in the body. Blood not only 
transports soluble biomarkers but because the leukocytes 
interact and communicate with practically every tissue, 
they bear rich information regarding inﬂ ammation and 
immune responses. Whole genome expression proﬁ ling 
of blood cells from RA patients has identiﬁ ed marker 
genes the expression of which predicts with 86% accuracy 
the response of inﬂ iximab in RA [4]. More importantly, 
only eight marker genes are needed to evaluate blood 
cells for a valid prediction. Another study showed that 
the expression of CD11c is a biomarker in monocytes to 
identify responders to abdalumimab [5]. Interestingly, 
the correlation of CD11c with response was lost when 
methotrexate was co-administered, showing the narrow 
window of CD11c as a predictive transcriptional bio-
marker. Many other genes are signiﬁ cantly upregulated in 
RA peripheral blood mononuclear cells compared to 
healthy controls - for example, those encoding CD14 
antigen, defensin-a1/3, and S100A proteins, which are of 
potential diagnostic and prognostic value for RA. Over 
the past decade, proteomics have yielded potential new 
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candidates in the quest for better biomarkers for RA, 
including the S100 proteins, serum amyloid A, alpha 
1-antitrypsin, and apolipoproteins in the blood [6]. In 
principle, carbohydrates, lipids and proteins (including 
enzymes, matrix proteins or their neoepitopes, 
autoantibodies, acute-phase proteins, chemokines, 
growth factors, cytokines and their inhibitors, and 
receptors) can be biomarkers for inﬂ ammation, 
connective tissue destruction, diagnosis and prognosis in 
RA (reviewed by Carrasco and Barton [7]).
Soluble IL-18 receptor complex
Cytokines and cytokine-related molecules play a key role 
in the pathogenesis of RA. Levels of TNFα, the soluble 
TNF receptor-II, and IL-6 are elevated in serum but, due 
to their short half-life and the complexity of the cytokine 
network, it remains to be determined whether they can 
be used as biomarkers in a clinical setting. IL-18 is a 
member of the IL-1 cytokine superfamily and plays a key 
role in the regulation of immunity and inﬂ ammation [8]. 
Its biological eﬀ ect is regulated at diﬀ erent levels. IL-18 is 
synthesized as a larger precursor protein that requires 
caspase-1-mediated cleavage for activation. For IL-18 cell 
signaling, IL-18 binds to the IL-18 receptor (IL-18R)α 
with relatively low aﬃ  nity and attracts the signal trans-
ducing IL-18Rβ chain (also termed the IL-1R accessory 
protein-like chain) to form a functional receptor 
complex. In vivo, its biological activity is also dependent 
on secreted IL-18 binding proteins and the soluble forms 
of both its receptors: IL-18Rα probably by enzymatic 
cleavage and IL-18Rβ as an alternative splicing event. 
Th eir regulatory properties might be diﬀ erent as IL-18 
binding protein ameliorates collagen-induced arthritis 
whereas soluble IL-18Rβ aggravates it [9,10]. Previously, 
Bresnihan and colleagues [11] demonstrated raised serum 
levels of IL-18 and its binding protein in RA patients 
compared to psoriatic arthritis patients, but this did not 
seem to correlate with response to therapy with metho-
trexate, whereas CRP levels did. Interestingly, IL-18 
protein expression in synovial tissue did correlate with 
serum CRP and disease activity in inﬂ ammatory arthritis 
[12], indicating a local role in the pathophysiology of 
disease. A comparative study of diﬀ erent biomarkers, 
either circulating or expressed in the synovial tissue, 
showed the utility of serum tissue inhibitor of metallo-
proteinases (TIMP) as predictive for a later therapeutic 
response to anakinra [13]. Th is study conﬁ rmed previous 
ﬁ ndings that serum IL-18 correlates poorly with disease 
activity and treatment response but is highly predictive 
for radiographic progression of the disease [13]. Th e 
study of Takei and colleagues [1] demonstrates that the 
systemic soluble IL-18Rα complex, which in vitro exhibits 
antagonistic activity, probably also contains a dimeric 
IL-18 protein and the soluble form of the IL-18Rβ chain. 
Th e serum levels of this complex were signiﬁ cantly higher 
in patients with RA and adult-onset Still’s disease than in 
healthy controls and osteoarthritis and systemic lupus 
erythematosus patients. Moreover, treatment of RA 
patients with the TNF inhibitor etanercept resulted in a 
signiﬁ cant improvement in serum levels of soluble IL-
18Rα complex. It remains to be seen whether the soluble 
IL-18Rα complex can be used for the evaluation of joint 
damage or disease activity but even so it could be useful 
for the diagnosis of RA Th e soluble IL-18Rα complex as a 
biomarker may capture the com plexity of the 
inﬂ ammatory process: the shedding of membrane 
IL-18Rα as a marker of enhanced proteolytic activity; the 
activation and release of IL-18 by the inﬂ ammasome as a 
marker of innate immunity; and the alternatively spliced 
soluble IL-18Rβ, which is mainly expressed in the 
lymphoid organs and regulates IL-18-driven T-cell 
immunity [10]. Currently, CRP is still a useful and reliable 
marker for disease activity and treatment response in the 
clinic. However, it is recog nized that combinations of 
biomarkers will greatly enhance the power for diagnosis 
and the soluble IL-18Rα complex may be useful in this 
regard for RA, but longitudinal studies and cross-
sectional analysis are warranted.
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